🔬 This acquisition enhances Ofichem’s ability to support clients from research to GMP production.
✨ CEO Weite H. Oldenziel emphasizes a commitment to innovation and a science-led approach.
📈 This aligns with Ofichem’s strategy for expanding services in Europe and North America.
Introduction:
The acquisition of Avivia by the Ofichem Group represents a strategic move aimed at enhancing formulation development capabilities and reinforcing Ofichem’s position as a comprehensive provider of drug development solutions. This article delves into the implications of this acquisition within the biopharmaceutical landscape.
- Ofichem Group has entered into a definitive agreement to acquire Avivia, a company specializing in formulation development based in the Netherlands.
- The acquisition is part of Ofichem’s strategy to become a fully integrated provider of development solutions, focusing on complex formulations.
- Avivia’s expertise includes formulation development, analytical method development, dissolution testing, and excipient characterization.
- This acquisition is expected to strengthen Ofichem’s capabilities in supporting drug development from early phases through to GMP (Good Manufacturing Practice) production.
- Ofichem is pursuing further opportunities to enhance its capabilities in Europe and North America, aligning with its broader mergers and acquisitions strategy and investment in innovative technologies.
Conclusion:
The acquisition of Avivia by Ofichem not only bolsters the company’s formulation development capabilities but also aligns with its goal of becoming a comprehensive service provider in the biopharmaceutical sector. This strategic move highlights Ofichem’s commitment to innovation and customer-centric solutions, while positioning it for further growth and development opportunities in the global market.
